phenylalanyl-prolyl-arginine-chloromethyl ketone has been researched along with glycine in 3 studies
Studies (phenylalanyl-prolyl-arginine-chloromethyl ketone) | Trials (phenylalanyl-prolyl-arginine-chloromethyl ketone) | Recent Studies (post-2010) (phenylalanyl-prolyl-arginine-chloromethyl ketone) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
---|---|---|---|---|---|
191 | 4 | 23 | 35,163 | 756 | 8,415 |
Protein | Taxonomy | phenylalanyl-prolyl-arginine-chloromethyl ketone (IC50) | glycine (IC50) |
---|---|---|---|
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Deinum, J; Elg, M; Gustafsson, D | 1 |
Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
Frebelius, S; Grip, L; Linder, R; Swedenborg, J | 1 |
1 review(s) available for phenylalanyl-prolyl-arginine-chloromethyl ketone and glycine
Article | Year |
---|---|
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
2 other study(ies) available for phenylalanyl-prolyl-arginine-chloromethyl ketone and glycine
Article | Year |
---|---|
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin | 2003 |